Journal of Clinical Oncology, Vol 3, 925-931, Copyright © 1985 by American Society of Clinical Oncology
Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity
M Markman, S Cleary, WE Lucas and SB Howell
Sixty-two patients with refractory ovarian carcinoma or other malignancies
principally confined to the peritoneal cavity were treated with an
intraperitoneal combination chemotherapy regimen consisting of cisplatin
(100 mg/m2 or 200 mg/m2) and cytosine arabinoside (4 X 10(-3) mol/L or
10(-2) mol/L). Sodium thiosulfate was simultaneously administered
intravenously (IV) to protect against cisplatin-induced nephrotoxicity.
Sixteen of 52 evaluable patients demonstrated evidence of a clinical
response including 14 (36%) of 39 with refractory ovarian carcinoma.
Systemic toxicity was not severe except for cisplatin- induced emesis and a
single episode of major renal insufficiency. Dose- limiting toxicity was
bone marrow suppression with cytosine arabinoside administered at 10(-2)
mol/L. We conclude that combination intraperitoneal therapy with high-dose
cisplatin and cytosine arbinoside can be safely administered with objective
tumor responses observed in patients with ovarian carcinoma refractory to
front-line chemotherapy and in occassional individuals with other
malignancies principally confined to the peritoneal cavity.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
